Left ventricular ejection fraction as a prognostic marker in atrial fibrillation management

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide and significantly contributes to morbidity and mortality, especially in older populations[1]. AF increases the risk of stroke, heart failure, and overall cardiovascular mortality[2]. It is categorized into two primary subtypes: paroxysmal (AF that spontaneously terminates within 7 days) and non-paroxysmal (which includes persistent and permanent AF). These subtypes exhibit distinct clinical characteristics and long-term outcomes. Management strategies for AF include rate and rhythm control, and anticoagulation to reduce stroke risk[3]. Left ventricular ejection fraction (LVEF), a critical measure of systolic function, is one of the most valuable predictors in determining the prognosis of patients with AF, particularly concerning heart failure and the risk of adverse cardiovascular events. A recent study analyzed 2054 patients with AF, focusing on the relationship between LVEF and AF subtypes[4]. The study found that 68.3% of the patients had non-paroxysmal AF and demonstrated a significantly lower LVEF than those with paroxysmal AF. Furthermore, as LVEF declined, the likelihood of presenting with non-paroxysmal AF increased, particularly in patients with hypertension and obesity. Patients with non-paroxysmal AF were also more likely to have higher rates of coronary artery disease (19%) and faster heart rates than those with paroxysmal AF. These findings highlight the role of LVEF as a prognostic marker for identifying AF progression and associated risks, emphasizing the need for careful management of these patients. LVEF is a crucial parameter in assessing heart pumping capacity and systolic function, especially in patients with cardiovascular disease. In the context of AF, reduced LVEF is closely associated with worse outcomes, including a higher risk of stroke, heart failure, and mortality[5-7] This relationship is even more pronounced in non-paroxysmal AF, where the sustained nature of arrhythmia can exacerbate ventricular dysfunction[8]. Studies have shown that AF itself can lead to a decrease in LVEF through mechanisms such as tachycardia-induced cardiomyopathy and atrial remodeling, worsening the clinical trajectory of these patients[9,10]. The association between reduced LVEF and adverse outcomes in AF patients has been well documented. In particular, patients with an LVEF < 40% have a significantly higher risk of developing heart failure, stroke, and even death[11]. This makes LVEF is a critical factor in determining the urgency of treatment and the choice between rate control, rhythm control, or more advanced interventions such as catheter ablation or device therapy. The clinical course and management of AF can vary significantly between paroxysmal and non-paroxysmal subtypes[12]. Paroxysmal AF is often associated with fewer long-term complications, and many patients remain asymptomatic for extended periods[13]. However, non-paroxysmal AF is a marker of more advanced disease, often associated with structural heart changes, such as left atrial enlargement and left ventricular dysfunction[14]. These patients are at higher risk for thromboembolic events, persistent arrhythmia, and heart failure progression. Non-paroxysmal AF is linked to an increased likelihood of requiring aggressive rhythm control strategies and closer monitoring for the development of heart failure or stroke[14]. Patients with nonparoxysmal AF often have higher comorbidity burdens, such as hypertension, diabetes, and coronary artery disease, which can complicate management and require a more comprehensive, multidisciplinary approach[15]. Hypertension and obesity are two of the most significant modifiable risk factors contributing to the development and progression of AF[16,17]. Both conditions promote structural and electrical remodeling of the atria, increasing the likelihood of developing non-paroxysmal AF[18]. Hypertension leads to left ventricular hypertrophy and increased atrial pressure, while obesity contributes to systemic inflammation and increased left atrial size, all of which exacerbate AF severity[19,20]. The interaction between hypertension, obesity, and reduced LVEF in patients with AF presents a particularly challenging scenario. Studies have shown that lifestyle modifications, including weight loss, blood pressure control, and improved physical activity, can significantly reduce the burden of AF and slow the progression from paroxysmal to non-paroxysmal forms[21]. Early intervention in these risk factors is critical to improving outcomes and preventing the long-term complications associated with advanced AF. Given the strong prognostic implications of LVEF in patients with AF, incorporating routine LVEF measurements into clinical practice is essential for optimizing treatment strategies. For patients with non-paroxysmal AF and reduced LVEF, clinicians should consider early and aggressive rhythm control, anticoagulation, and management of comorbid conditions such as hypertension and obesity. The findings of studies on LVEF and AF subtypes suggest that more targeted interventions, including ablation or device-based therapies, may be necessary for patients with reduced LVEF and non-paroxysmal AF. Future research should focus on exploring novel therapeutic options for improving LVEF in patients with AF as well as to better understand the mechanisms by which AF leads to systolic dysfunction. Moreover, longitudinal studies are needed to evaluate the long-term benefits of early intervention in patients with reduced LVEF and non-paroxysmal AF to prevent progression to more severe cardiovascular outcomes. In conclusion, left ventricular ejection fraction is a vital prognostic marker in patients with atrial fibrillation, particularly in those with non-paroxysmal AF. The association between lower LVEF and an increased risk of adverse outcomes underscores the importance of regular LVEF monitoring in patients with AF. Addressing risk factors such as hypertension and obesity early in the disease course may help prevent AF progression and improve long-term outcomes. As research continues to evolve, incorporating LVEF assessments into routine AF management is essential for optimizing patient care and reducing the burden of cardiovascular complications.